Emerging targets, including Trop-2, B7-H3, ICAM-1, and GPRC5D, show restricted normal tissue expression and broad tumor prevalence, making them promising candidates for next-generation BsAbs.66 The gene discussed is ICAM1; the disease is neoplasm.